APEN - エルパス （Apollo Endosurgery Inc.） エルパスAPENのチャート
APENの企業情報
| symbol | APEN |
|---|---|
| 会社名 | Apollo Endosurgery Inc （エルパス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 Apollo Endosurgery Inc. formerly Lpath Inc. is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity as well as other gastrointestinal disorders. The Company''s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company''s products include ORBERA LAP-BAND and OverStitch. The Company''s product ORBERA is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract. エルパスは、米国のバイオテクノロジ―企業。｢lipidomic｣ベ―スの治療抗体の発見と開発に焦点を当てたる｡｢ iSONEP｣は､sonepcizumabの眼の製剤。｢ASONEP｣は、癌の様々な腫瘍タイプを治療するために処方されsonepcizumabの全身性製剤、および腎細胞癌を有する患者の治療薬。 Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. |
| 本社所在地 | 1120 S. Capital of Texas Highway Building 1 Suite #300 Austin TX 78746 USA |
| 代表者氏名 | Richard J. Meelia リチャード・J・ミエリア |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 512-279-5100 |
| 設立年月日 | － |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 213人 |
| url | www.apolloendo.com |
| nasdaq_url | https://www.nasdaq.com/symbol/apen |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.77900 |
| 終値（lastsale） | 6.9199 |
| 時価総額（marketcap） | 151399772.4304 |
| 時価総額 | 時価総額（百万ドル） 148.33890 |
| 売上高 | 売上高（百万ドル） 64.21500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 147.26790 |
| 当期純利益 | 当期純利益（百万ドル） -29.89200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Apollo Endosurgery Inc revenues decreased less than 1% to $31.5M. Net loss increased 17% to $17.7M. Revenues reflect Endo-bariatric segment increase of 25% to $21.1M Other segment increase of 49% to $543K also reflect Surgical segment decrease of 32% to $9.9M United States segment decrease of 14% to $14.5M. Higher net loss reflects Research and development increase of 32% to $5.6M |
APENのテクニカル分析
APENのニュース
This Analyst Thinks Apollo Endosurgery''s Valuation ''Does Not Assign Full Value'' - Read Why 2022/05/04 20:00:31 Benzinga
Stephens has reiterated an Overweight rating for Apollo Endosurgery Inc (NASDAQ: APEN ) while increasing the price target from $8 to $9 . "In our opinion, APEN''s valuation does not assign full value to the promising ESS business or targeted opportunities for expanded device utilization and enhanced reimbursement longer term," says Stephens. The revision follows APEN''s above consensus 1Q22 revenue growth and reiterates previously established CY22 revenue guidance. The intragastric balloon (IGB) franchise remains the primary contributor to the … Full story available on Benzinga.com
Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q1 2022 Results - Earnings Call Transcript 2022/05/04 03:06:02 Seeking Alpha
Apollo Endosurgery, Inc. (NASDAQ:NASDAQ:APEN) Q1 2022 Earnings Conference Call May 03, 2022 04:30 PM ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive…
Apollo Endosurgery, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:APEN) 2022/05/03 22:53:47 Seeking Alpha
The following slide deck was published by Apollo Endosurgery, Inc.
Apollo Endosurgery GAAP EPS of -$0.21 in-line, revenue of $16.7M beats by $0.77M 2022/05/03 20:03:54 Seeking Alpha
Apollo Endosurgery, Inc. Reports 33% U.S. Revenue Growth in First Quarter 2022 2022/05/03 20:01:00 Wallstreet:Online
Global revenue grew 20% year-over-year as adoption increased across all product linesAUSTIN, TX / ACCESSWIRE / May 3, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and …
Apollo Endosurgery to Report First Quarter Results on May 3, 2022 2022/04/13 12:45:00 Wallstreet:Online
AUSTIN, TX / ACCESSWIRE / April 13, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (Nasdaq:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the …
Global Intragastric Balloons Market to 2029 - Featuring Allurion Technologies, Apollo Endosurgery and Districlass Medical Among Others - ResearchAndMarkets.com 2022/04/12 11:34:00 Benzinga
The "Intragastric Balloons Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com''s offering. This report provides manufacturers, business executives, and shareholders with a comprehensive study helping them in designing the roadmap associated with the anticipation in the global intragastric balloons market; and to help them in taking collaborative decision. This report investigates and gives the latest trends prevailing in the global intragastric balloons market, and the forecast and market size. Obesity is a complex medical condition which leads to critical health complications such as diabetes, heart diseases high blood pressure and more. Prevalence of obesity along with comorbid diseases associated with overweighing and obesity should drive the global market. According to the World Health Organization (WHO), the global obese population has tripled since 1975.
Global Medical Weight-Loss Devices Market Size to 2028 By Upcoming Trends and Challenges, Industry Revenue, Growth Factors, Future Strategic Planning, Key Vendors, Market Contribution and Developments 2022/03/21 10:08:47 Benzinga
Pune, March 21, 2022 (GLOBE NEWSWIRE) -- Global " Medical Weight-Loss Devices Market " report explores Comprehensive and Insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. The Medical Weight-Loss Devices market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of Current Market Dynamics, Future Developments, and Porter''s Five Forces Analysis. Get a Sample PDF of report - https://www.industryresearch.biz/enquiry/request-sample/20167810 Market Analysis and Insights: Global Medical Weight-Loss Devices Market Fully considering the economic change by this health crisis, Gastric Band accounting for % of the Medical Weight-Loss Devices global market in 2021, is projected to value USD million by 2028, growing at a revised % CAGR in the post-COVID-19 period.
Apollo Endosurgery up 17% after CFO adds shares 2022/03/02 19:15:06 Seeking Alpha
Apollo Endosurgery <> jumps after CFO Jeffrey G
Apollo Endosurgery, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/02/23 08:04:31 Seeking Alpha
Apollo Endosurgery up 17% after CFO adds shares 2022/03/02 19:15:06 Seeking Alpha
Apollo Endosurgery <> jumps after CFO Jeffrey G
Apollo Endosurgery, Inc. 2021 Q4 - Results - Earnings Call Presentation 2022/02/23 08:04:31 Seeking Alpha
Apollo Endosurgery, Inc. (APEN) CEO Charles McKhann on Q4 2021 Results - Earnings Call Transcript 2022/02/23 01:45:27 Seeking Alpha
Apollo Endosurgery GAAP EPS of -$0.27 misses by $0.09, revenue of $16.2M in-line 2022/02/22 21:22:20 Seeking Alpha
Apollo Endosurgery press release (APEN): Q4 GAAP EPS of -$0.27 misses by $0.09.Revenue of $16.2M (+26.0% Y/Y) in-line.
Apollo Endosurgery Inc Shares Close the Week 22.6% Lower - Weekly Wrap 2022/01/19 20:37:34 Kwhen Finance
Apollo Endosurgery Inc (APEN) shares closed this week 22.6% lower than it did at the end of last week. The stock is currently down 32.7% year-to-date, up 45.4% over the past 12 months, and down 63.7% over the past five years. This week, the Dow Jones Industrial Average fell 2.4%, and the S&P 500 fell 2.8%. Trading Activity Shares traded as high as $7.52 and as low as $5.63 this week.Trading volume this week was 2.7% higher than the 10-day average and 44.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -494.2% The company's stock price performance over the past 12 months beats the peer average by 169.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.